Skip to main content

Advertisement

SpringerLink
Log in

Long-term interferon therapy after radiofrequency ablation is effective in treating patients with HCV-associated hepatocellular carcinoma

  • Original Article
  • Published:
Hepatology International Aims and scope Submit manuscript

Abstract

Purpose

This study investigates the usefulness of long-term interferon (IFN) therapy following radiofrequency ablation (RFA) for HCV-associated hepatocellular carcinoma (HCC).

Methods

This is a retrospective observational study. Patients underwent pegylated IFN-α/ribavirin combination therapy for 48 weeks and then were maintained on IFN-α administration on average for 68 weeks (mean total duration 116 weeks). Patients who underwent IFN monotherapy were maintained on IFN administration on average for 78 weeks.

Results

There were biases in the background factors between the IFN and non-IFN groups. Therefore, a covariate adjustment was performed using the propensity score. An analysis of 20-matched patients from each group showed the 5-year cumulative survival rate was higher in the IFN group than in the non-IFN group (100 and 76%, respectively), and the 3-year cumulative recurrence rate was significantly lower in the IFN group than in the non-IFN group (38.0 and 64.2%, respectively). In 14 patients (i.e., IFN responders), the serum alanine aminotransferase (ALT) level remained normalized at 30 IU/mL or lower, regardless of disappearance of serum HCV RNA. In these patients, the cumulative recurrence rate was low, the hazard ratio was 0.158 (95% confidence interval = 0.045–0.561, P = 0.004), and the serum albumin level was retained.

Conclusion

These results show the importance of maintaining the liver function and suggest that long-term IFN administration after RFA inhibits recurrence and contributes to an improved outcome in patients (in particular, IFN responders) who initially develop HCC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Hashem B, Lenhard R. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007;132:2557–2576

    Article  Google Scholar 

  2. Koike K, Tsutsumi T, Fujie H, Shintani Y, Moriya K. Molecular mechanism of viral hepatocarcinogenesis. Oncology 2002;62(Suppl 19):29–37

    Article  PubMed  Google Scholar 

  3. Imamura H, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa K, Miyagawa S, Sugawara Y, Minagawa M, Takayama T, Kawasaki S, Makuuchi M. Risk factor contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 2003;38:200–203

    Article  PubMed  Google Scholar 

  4. Ikeda K, Arase Y, Kobayashi M, Saitoh S, Someya T, Hosaka T, Suzuki Y, Suzuki F, Tsubota A, Akuta N, Kumada H. Significance of multicentric cancer recurrence after potentially curative ablation of hepatocellular carcinoma: a longterm cohort study of 892 patients with viral cirrhosis. J Gastroenterol 2003;38:865–876

    Article  PubMed  Google Scholar 

  5. Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S, Shiomi S, Seki S, Kobayashi K, Otani S. Randomised trial of effects of Interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995;346:1051–1055

    Article  CAS  PubMed  Google Scholar 

  6. Nishiguchi S, Shiomi S, Nakatani S, Takeda T, Fukuda K, Tamori A, Habu D, Tanaka T. Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis. Lancet 2001;357:196–197

    Article  CAS  PubMed  Google Scholar 

  7. Yoshida H, Arakawa Y, Sata M, Nishiguchi S, Yano M, Fujiyama S, Yamada G, Yokosuka O, Shiratori Y, Omata M. Interferon therapy prolonged life expectancy among chronic hepatitis C patients. Gastroenterology 2002;123:483–491

    Article  CAS  PubMed  Google Scholar 

  8. Shiratori Y, Ito Y, Yokosuka O, Imazeki F, Nakata R, Tanaka N, Arakawa Y, Hashimoto E, Hirata K, Yoshida H, Ohashi Y, Omata M. Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. Ann Intern Med 2005;142:105–114

    CAS  PubMed  Google Scholar 

  9. Kurokawa M, Hiramatsu N, Oze T, Mochizuki K, Yakushijin T, Kurashige N, Inoue Y, Igura T, Imanaka K, Yamada A, Oshita M, Hagiwara H, Ito T, Inui Y, Hijioka T, Yoshihara H, Inoue A, Imai Y, Kato M, Kiso S, Kanto T, Takehara T, Kasahara A, Hayashi N. Effect of interferon α-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with chronic hepatitis. Hepatol Res 2009;39:432–438

    Article  CAS  PubMed  Google Scholar 

  10. Ikeda K, Arase Y, Saitoh S, Kobayashi M, Suzuki Y, Suzuki F, Tsubota A, Chayama K, Murashima N, Kumada H. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor―a prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 2000;32:228–232

    Article  CAS  PubMed  Google Scholar 

  11. Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, Kinoshita H. Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hapatocellular carcinoma by postoperative interferon therapy. Br J Surg 2002;89:418–422

    Article  CAS  PubMed  Google Scholar 

  12. Shiratori Y, Shiina S, Teratani T, Imamura M, Obi S, Sato S, Koike Y, Yoshida H, Omata M. Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med 2003;138:299–306

    PubMed  Google Scholar 

  13. Nishiguchi S, Tamori A, Kubo S. Effect of long-term postoperative interferon therapy on intrahepatic recurrence and survival rate after resection of hepatitis C virus-related hepatocellular carcinoma. Intervirology 2005;48:71–75

    Article  CAS  PubMed  Google Scholar 

  14. Jeong SC, Aikata H, Katamura Y, Azakami T, Kuwaoka T, Saneto H, Uka K, Mori N, Takaki S, Kodama H, Waki K, Imamura M, Shirakawa H, Kawakami Y, Takahashi S, Chayama K. Effects of a 24-week course of interferon-α therapy after curative treatment of hepatitis C virus- associated hepatocellular carcinoma. World J Gastroenterol 2007;13:5343–5350

    PubMed  Google Scholar 

  15. Kudo M, Sakaguchi Y, Chung H, Hatanaka K, Hagiwara S, Ishikawa E, Takahashi S, Kitai S, Inoue T, Minami Y, Ueshima K. Long-term interferon maintenance therapy improves survival in patients with hepatitis C virus-related hepatocellular carcinoma after curative radiofrequency ablation. Oncology 2007;72(Suppl 1):132–138

    Article  CAS  PubMed  Google Scholar 

  16. Mazzaferro V, Romito R, Schiavo M, Mariani L, Camerini T, Bhoori S, Capussotti L, Calise F, Pellicci R, Belli G, Tagger A, Colombo M, Bonino F, Majno P, Liovet JM. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in hepatitis C virus cirrhosis. Hepatology 2006;44:1543–1554

    Article  CAS  PubMed  Google Scholar 

  17. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983;70:41–55

    Article  Google Scholar 

  18. D’Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998;17:2265–2281

    Article  PubMed  Google Scholar 

  19. Minagawa M, Ikai I, Matsuyama Y, Yamaoka Y, Makuuchi M. Staging of hepatocellular carcinoma: assessment of the Japanese Tumor-Node-Metastasis and American Joint Committee on Cancer/International Union Against Cancer Tumor-Node-Metastasis systems in a cohort of 13,772 patients in Japan. Ann Surg 2007;245:909–922

    Article  PubMed  Google Scholar 

  20. Weitzen S, Lapane KL, Toledano AY, Hume AL, Mor V. Weaknesses of goodness-of-fit tests for evaluating propensity score models. Pharmacoepidemiol Drug Saf 2005;14:227–238

    Article  PubMed  Google Scholar 

  21. Koike K. Pathogenesis of hepatitis C virus-associated hepatocellular carcinoma: dual-pass carcinogenesis through activation of oxidative stress and intracellular signaling. Hepatol Res 2007;37:115–120

    Article  Google Scholar 

  22. Kumada T, Nakano S, Takeda I, Sugiyama K, Osada T, Kiriyama S, Sone Y, Toyoda H, Shimada S, Takahashi M, Sassa T. Pattern of recurrence after initial treatment in patients with small hepatocellular carcinoma. Hepatology 1997;25:87–92

    Article  CAS  PubMed  Google Scholar 

  23. Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuubhi T, Kitamura T, Nakanishi K, Fujimoto I, Inoue A, Yamazaki H, Kawashima T. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993;328:1797–1801

    Article  CAS  PubMed  Google Scholar 

  24. Iwashyna TJ, Lamont EB. Effectiveness of adjuvant fluorouracil in clinical practice: a population-based cohort study of elderly patients with stage III colon cancer. J Clin Oncol 2002;20:3992–3998

    Article  CAS  PubMed  Google Scholar 

  25. Wang PS, Schneeweiss S, Avorn J, Fischer MA, Mogun H, Solomon DH, Brookhart MA. Risk of death in elderly users of conventional versus atypical antipsychotic medications. N Engl J Med 2005;353:2335–2341

    Article  CAS  PubMed  Google Scholar 

  26. Yano H, Iemura A, Haramaki M, Ogasawara S, Takayama A, Akiba J, Kojiro M. Interferon alfa receptor expression and growth inhibition by interferon alfa in human liver cancer cell lines. Hepatology 1999;29:1708–1717

    Article  CAS  PubMed  Google Scholar 

  27. Lai CL, Lau JY, Wu PC, Ngan H, Chung HT, Mitchell S, Corbett TJ, Chow AW, Lin HJ. Recombinant interferon-alpha in inoperable hepatocellular carcinoma: a randomized controlled trial. Hepatology 1993;17:389–394

    Article  CAS  PubMed  Google Scholar 

  28. Ota H, Nagano H, Sakon M, Eguchi H, Kondo M, Yamamoto T, Nakamura M, Damdinsuren B, Wada H, Marubashi S, Miyamoto A, Done K, Umeshita K, Nakamori S, Wakasa K, Monden M. Treatment of hepatocellular carcinoma with major portal vein thrombosis by combination of subcutaneous interferon-α and intraarterial 5-fluorouracil: role of expression of type 1 interferon receptor. Br J Cancer 2005;93:557–564

    Article  CAS  PubMed  Google Scholar 

  29. Yano H, Ogasawara S, Momosaki S, Akiba J, Kojiro S, Fukahori S, Ishizaki H, Kuratomi K, Basaki Y, Oie S, Kuwano M, Kojiro M. Growth inhibitory effects of pegylated interferon alpha-2b on human liver cancer cells in vitro and in vivo. Liver Int 2006;26:964–975

    Article  CAS  PubMed  Google Scholar 

  30. Wang L, Tang ZY, Qin LX, Wu XF, Sun HC, Xue Q, Ye SL. High-dose and long-term therapy with interferon-alfa inhibits tumor growth and recurrence in nude mice bearing human hepatocellular carcinoma xenografts with high metastatic potential. Hepatology 2000;32:43–48

    Article  CAS  PubMed  Google Scholar 

  31. Uenishi T, Nishiguchi S, Tamori A, Yamamoto T, Shuto T, Hirohashi K, Takemura S, Tanaka H, Kubo S. Influence of interferon therapy on outcome after surgery for hepatitis C virus-related hepatocellular carcinoma. Hepatol Res 2006;36:195–200

    Article  CAS  PubMed  Google Scholar 

  32. Zhang CH, Xu GL, Jia WD, Ge YS. Effects of interferon alpha treatment on recurrence and survival after complete resection or ablation of hepatocellular carcinoma: a meta-analysis of randomized controlled trials. Int J Cancer 2009;124:2982–2988

    Article  CAS  PubMed  Google Scholar 

  33. Shen YC, Hsu C, Chen LT, Cheng CC, Hu FC, Cheng AL. Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): a meta-regression approach. J Hepatol 2010;52:889–894

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hepatobiliary and Pancreatic Disease, Department of Internal Medicine, Hyogo College of Medicine, 1-1, Mukogawa-cho, Nishinomiya, Hyogo, 663-8501, Japan

    Soji Shimomura, Naoto Ikeda, Masaki Saito, Akio Ishii, Tomoyuki Takashima, Yoshiyuki Sakai, Shohei Yoshikawa, Nobuhiro Aizawa, Hironori Tanaka, Yoshinori Iwata, Hirayuki Enomoto, Hiroyasu Imanishi, Hideji Nakamura, Hiroko Iijima & Shuhei Nishiguchi

  2. Department of Gastrointestinal Medicine, Wakakusa-Daiichi Hospital, Osaka, Japan

    Teruhisa Yamamoto

  3. Department of Internal Medicine, Wakakoukai Clinic, Osaka, Japan

    Hisato Jomura

Authors
  1. Soji Shimomura
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Naoto Ikeda
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Masaki Saito
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Akio Ishii
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tomoyuki Takashima
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yoshiyuki Sakai
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Shohei Yoshikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Nobuhiro Aizawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Hironori Tanaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Yoshinori Iwata
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Hirayuki Enomoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Hiroyasu Imanishi
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Teruhisa Yamamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Hisato Jomura
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Hideji Nakamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Hiroko Iijima
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Shuhei Nishiguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Soji Shimomura.

Additional information

S. Shimomura and N. Ikeda equally contributed to this study.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shimomura, S., Ikeda, N., Saito, M. et al. Long-term interferon therapy after radiofrequency ablation is effective in treating patients with HCV-associated hepatocellular carcinoma. Hepatol Int 5, 559–566 (2011). https://doi.org/10.1007/s12072-010-9214-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12072-010-9214-2

Keywords

Search

Navigation